Literature DB >> 20440205

Management of dyspnea in advanced lung cancer: recent data and emerging concepts.

Dong Xue1, Amy P Abernethy.   

Abstract

PURPOSE OF REVIEW: One of the most common symptoms for lung cancer patients, dyspnea, can seriously impact patients' quality of life. RECENT
FINDINGS: Alongside conventional disease-focused approaches in lung cancer treatment, notably surgery, chemotherapy, and radiation therapy, physicians and researchers alike are increasingly attending to symptom control and seeking to evaluate the effectiveness of available interventions in mitigating symptoms.
SUMMARY: This study reviews several interesting advances in the area of dyspnea with respect to symptom assessment and management.

Entities:  

Mesh:

Year:  2010        PMID: 20440205     DOI: 10.1097/SPC.0b013e328339920d

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  3 in total

1.  Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21.

Authors:  Qing Yang; Zhi Zhang; Haixia Xu; Chuangen Ma
Journal:  Mol Cell Biochem       Date:  2019-01-14       Impact factor: 3.396

2.  Integrating palliative care with intensive care for critically ill patients with lung cancer.

Authors:  Elizabeth B Gay; Stefanie P Weiss; Judith E Nelson
Journal:  Ann Intensive Care       Date:  2012-02-16       Impact factor: 6.925

3.  Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial.

Authors:  Joshua Bauml; Andrew Haas; Charles B Simone; Susan Q Li; Roger B Cohen; Corey J Langer; Jun J Mao
Journal:  Integr Cancer Ther       Date:  2016-04-24       Impact factor: 3.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.